Physician profile
Robert J Vasquez
NPI 1255592374
$5,815.97
in general payments reported to CMS, 2019-2025
25 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2021: $12.88 · 2022: $3,691 · 2023: $449 · 2024: $724 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,698.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $3,290.14 | 2019-2022 | |
| Y-Mabs Therapeutics, INC. | $345.59 | 2022-2025 | Danyelza |
| Sobi, INC | $293.98 | 2022-2024 | |
| Seagen INC. | $235.94 | 2019-2023 | Adcetris |
| Amgen INC. | $233.33 | 2019-2022 | |
| Genetix Biotherapeutics INC | $198.20 | 2023 | |
| Genzyme Corporation | $177.87 | 2024-2025 | |
| Novo Nordisk INC | $157.98 | 2019-2025 | |
| Incyte Corporation | $124.97 | 2022 | |
| Novartis Pharmaceuticals Corporation | $122.85 | 2023-2024 | |
| Springworks Therapeutics, INC. | $109.69 | 2024-2025 | Ogsiveo, Gomekli |
| Tempus Ai, INC | $103.32 | 2024 | |
| Alexion Pharmaceuticals, INC. | $73.27 | 2022-2024 | Koselugo |
| Pfizer INC. | $65.04 | 2023-2024 | |
| Astellas Pharma US INC | $64.93 | 2024 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $55.37 | 2024-2025 | Hemlibra, Xolair, Activase |
| Takeda Pharmaceuticals U.S.A., INC. | $28.65 | 2025 | Vpriv |
| Pharmacyclics LLC, An Abbvie Company | $25.73 | 2022 | |
| Octapharma USA, INC. | $24.20 | 2025 | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) |
| Servier Pharmaceuticals LLC | $19.79 | 2024 | |
| Day One Biopharmaceuticals | $18.78 | 2025 | Ojemda |
| Hema Biologics, LLC | $17.01 | 2024 | Sevenfact |
| Syndax Pharmaceuticals, INC. | $16.46 | 2025 | |
| Global Blood Therapeutics, INC. | $12.88 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Vasquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.